My Portfolio
+
LINK YOUR PORTFOLIO

Prokidney Corp PROK:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
1.73quote price arrow down-0.17 (-8.95%)
Volume
832,349
52 week range
0.54 - 7.13
Loading...
  • Open1.86
  • Day High1.86
  • Day Low1.72
  • Prev Close1.90
  • 52 Week High7.13
  • 52 Week High Date07/09/25
  • 52 Week Low0.54
  • 52 Week Low Date06/30/25

Latest On Prokidney Corp

 

Key Stats

  • Market Cap522.563M
  • Shares Out302.06M
  • 10 Day Average Volume1.16M
  • Dividend-
  • Dividend Yield-
  • Beta1.70

Latest On Prokidney Corp

 

KEY STATS

  • Open1.86
  • Day High1.86
  • Day Low1.72
  • Prev Close1.90
  • 52 Week High7.13
  • 52 Week High Date07/09/25
  • 52 Week Low0.54
  • 52 Week Low Date06/30/25
  • Market Cap522.563M
  • Shares Out302.06M
  • 10 Day Average Volume1.16M
  • Dividend-
  • Dividend Yield-
  • Beta1.70

RATIOS/PROFITABILITY

  • EPS (TTM)-0.53
  • P/E (TTM)-3.30
  • Fwd P/E (NTM)-2.80
  • EBITDA (TTM)-161.575M
  • ROE (TTM)-7.28%
  • Revenue (TTM)889,000.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-17,579.42%
  • Debt To Equity (MRQ)-0.01%

EVENTS

  • Earnings Date08/11/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney...
Pablo Legorreta
Chairman of the Board
Bruce Culleton M.D.
Chief Executive Officer, Director
James Coulston CPA
Chief Financial Officer
Address
2000 Frontis Plaza Blvd, Suite 250
Winston-salem, NC
27103
United States